IN2012DN06720A - - Google Patents

Info

Publication number
IN2012DN06720A
IN2012DN06720A IN6720DEN2012A IN2012DN06720A IN 2012DN06720 A IN2012DN06720 A IN 2012DN06720A IN 6720DEN2012 A IN6720DEN2012 A IN 6720DEN2012A IN 2012DN06720 A IN2012DN06720 A IN 2012DN06720A
Authority
IN
India
Prior art keywords
disease
treatment
present disclosure
disclosure relates
pharmaceutical formulations
Prior art date
Application number
Inventor
Dingjiang Liu
Holly Zhuohong Huang
David Andrew Martin
Christopher Boyd Russell
David H Salinger
Scott Walter Baumgartner
Christopher J Endres
Original Assignee
Kirin Amgen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=43858045&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=IN2012DN06720(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Kirin Amgen Inc filed Critical Kirin Amgen Inc
Publication of IN2012DN06720A publication Critical patent/IN2012DN06720A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39591—Stabilisation, fragmentation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0021—Intradermal administration, e.g. through microneedle arrays, needleless injectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Abstract

The present disclosure relates to AM 14 pharmaceutical formulations and therapeutic dosing regimens for the treatment of disease.
IN6720DEN2012 2010-01-15 2011-01-12 IN2012DN06720A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US29538710P 2010-01-15 2010-01-15
US42205910P 2010-12-10 2010-12-10
PCT/US2011/020985 WO2011088120A1 (en) 2010-01-15 2011-01-12 Antibody formulation and therapeutic regimens

Publications (1)

Publication Number Publication Date
IN2012DN06720A true IN2012DN06720A (en) 2015-10-23

Family

ID=43858045

Family Applications (1)

Application Number Title Priority Date Filing Date
IN6720DEN2012 IN2012DN06720A (en) 2010-01-15 2011-01-12

Country Status (37)

Country Link
US (5) US8883151B2 (en)
EP (3) EP3632466A1 (en)
JP (2) JP5743234B2 (en)
KR (1) KR101766936B1 (en)
CN (1) CN102821787B (en)
AR (1) AR079903A1 (en)
AU (3) AU2011205402B2 (en)
BR (1) BR112012017150B1 (en)
CA (1) CA2787128C (en)
CL (1) CL2012001966A1 (en)
CO (1) CO6640206A2 (en)
CR (1) CR20120419A (en)
CY (2) CY1119852T1 (en)
DK (2) DK2523688T3 (en)
EA (2) EA201891433A3 (en)
ES (2) ES2753216T3 (en)
HR (1) HRP20171939T1 (en)
HU (2) HUE046670T2 (en)
IL (1) IL220602B (en)
IN (1) IN2012DN06720A (en)
LT (2) LT2523688T (en)
MA (1) MA33989B1 (en)
MX (1) MX349856B (en)
MY (1) MY182680A (en)
NO (1) NO2523688T3 (en)
NZ (1) NZ601125A (en)
PE (1) PE20121691A1 (en)
PL (2) PL2523688T3 (en)
PT (2) PT3295957T (en)
RS (2) RS59743B1 (en)
SG (2) SG182468A1 (en)
SI (2) SI3295957T1 (en)
TN (1) TN2012000335A1 (en)
TW (1) TWI554282B (en)
UA (1) UA112288C2 (en)
WO (1) WO2011088120A1 (en)
ZA (1) ZA201205167B (en)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7767206B2 (en) 2006-10-02 2010-08-03 Amgen Inc. Neutralizing determinants of IL-17 Receptor A and antibodies that bind thereto
JO3244B1 (en) 2009-10-26 2018-03-08 Amgen Inc Human il-23 antigen binding proteins
PE20121691A1 (en) * 2010-01-15 2012-12-14 Kirin Amgen Inc FORMULATION OF ANTIBODIES AND THERAPEUTIC REGIMES
AU2011212440B2 (en) * 2010-02-04 2015-01-22 Csl Behring Ag Immunoglobulin preparation
EP3546483A1 (en) 2010-05-20 2019-10-02 Ablynx N.V. Biological materials related to her3
CA2814780C (en) 2010-09-22 2017-05-16 Amgen Inc. Carrier immunoglobulins and uses thereof
EA201391488A1 (en) * 2011-04-07 2014-01-30 ГЛЭКСОСМИТКЛАЙН ЭлЭлСи COMPOSITIONS WITH REDUCED VISCOSITY
UA117218C2 (en) 2011-05-05 2018-07-10 Мерк Патент Гмбх Amino acid sequences directed against il-17a, il-17f and/or il17-a/f and polypeptides comprising the same
JOP20200043A1 (en) * 2011-05-10 2017-06-16 Amgen Inc Methods of treating or preventing cholesterol related disorders
WO2013016220A1 (en) * 2011-07-22 2013-01-31 Amgen Inc. Il-17 receptor a is required for il-17c biology
EP3492099A1 (en) * 2011-11-23 2019-06-05 Amgen Inc. Administration of alpha4beta7 hetero-dimer-specific antibody
UA114620C2 (en) * 2012-03-07 2017-07-10 Елі Ліллі Енд Компані Il-17 antibody formulation
EP3184542A1 (en) 2012-05-14 2017-06-28 Novo Nordisk A/S Stabilised protein solutions
EP2968488A1 (en) 2013-03-15 2016-01-20 Amgen Inc. Methods for treating psoriasis using an anti-il-23 antibody
EP2968486A1 (en) 2013-03-15 2016-01-20 Amgen Inc. Methods for treating crohn's disease using an anti-il23 antibody
EP3126392B1 (en) * 2014-03-31 2019-09-11 Kirin-Amgen, Inc. Methods of treating nail and scalp psoriasis
MX2016014761A (en) 2014-05-16 2017-05-25 Amgen Inc Assay for detecting th1 and th2 cell populations.
MY186840A (en) * 2014-08-26 2021-08-25 Amgen K A Inc Method for treating psoriasis patient which received anti-tnf-alpha antibody therapy
EP3193171B1 (en) * 2014-09-10 2019-05-29 NOF Corporation Use of a protein adsorption inhibitor and method for inhibiting protein adsorption
CN108290058B (en) 2015-09-17 2023-05-16 美国安进公司 Predicting clinical response of IL23 antagonists using IL23 pathway biomarkers
AU2016349113A1 (en) 2015-11-04 2018-06-07 Astrazeneca Ab Dipeptidyl peptidase-4 and periostin as predictors of clinical response to eosinophil-targeted therapeutic agents in eosinophilic diseases
WO2017112536A1 (en) 2015-12-22 2017-06-29 Amgen Inc. Ccl20 as a predictor of clinical response to il23-antagonists
CN114265251A (en) 2016-04-19 2022-04-01 Sage电致变色显示有限公司 Electrochromic device including transparent conductive oxide layer and bus bar and method of forming the same
GB201612043D0 (en) * 2016-07-11 2016-08-24 Crescendo Biologics Ltd Composition for treatment of disorders
CA2974531A1 (en) * 2017-07-26 2019-01-26 Michael Giroux Safety anchor and roof vent
GB201719447D0 (en) 2017-11-23 2018-01-10 Ucb Biopharma Sprl Pharmaceutical composition
KR20210032441A (en) 2018-07-13 2021-03-24 아스트라제네카 콜라보레이션 벤처스, 엘엘씨 Treatment of Ulcerative Colitis with Brajicumab
AU2020225202B2 (en) 2019-02-18 2023-10-26 Eli Lilly And Company Therapeutic antibody formulation
WO2021050563A1 (en) * 2019-09-09 2021-03-18 The Rockefeller University Antibody treatment for lesional tissue of hidradenitis suppurativa
CA3150951A1 (en) 2019-09-11 2021-03-18 Bausch Health Ireland Limited Methods of treating nonalcoholic fatty liver disease (nafld) using il-17ra antibody
CN111840217B (en) * 2020-06-19 2021-04-02 北京东方百泰生物科技股份有限公司 Injection preparation of anti-IL-17 RA monoclonal antibody
KR20240021800A (en) * 2021-05-12 2024-02-19 아납티스바이오, 아이엔씨. antibody composition
WO2023240071A1 (en) * 2022-06-06 2023-12-14 Fusion Pharmaceuticals Inc. Methods of dosing therapeutic agents

Family Cites Families (99)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US1000835A (en) 1911-06-19 1911-08-15 Stewart A Minnick Calipers.
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
IL83878A (en) 1987-09-13 1995-07-31 Yeda Res & Dev Soluble protein corresponding to tnf inhibitory protein its preparation and pharmaceutical compositions containing it
IL98078A0 (en) 1991-05-07 1992-06-21 Yeda Res & Dev Pharmaceutical compositions comprising an anticytokyne
US5204244A (en) 1987-10-27 1993-04-20 Oncogen Production of chimeric antibodies by homologous recombination
GB8807803D0 (en) 1988-03-31 1988-05-05 Glaxo Group Ltd Biochemical product
WO1989009622A1 (en) 1988-04-15 1989-10-19 Protein Design Labs, Inc. Il-2 receptor-specific chimeric antibodies
IL94039A (en) 1989-08-06 2006-09-05 Yeda Res & Dev Antibodies to tbp - 1 and their use
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5116964A (en) 1989-02-23 1992-05-26 Genentech, Inc. Hybrid immunoglobulins
DE59010941D1 (en) 1989-04-21 2005-03-24 Amgen Inc TNF receptor, TNF-binding proteins and DNAs coding therefor
DE3922089A1 (en) 1989-05-09 1990-12-13 Basf Ag NEW PROTEINS AND THEIR PRODUCTION
DE69017753T3 (en) 1989-05-18 2013-06-20 Yeda Research And Development Co., Ltd. Tumor necrosis factor binding protein II, its purification and specific antibodies
IL95031A (en) 1989-07-18 2007-03-08 Amgen Inc Method for the production of a human recombinant tumor necrosis factor inhibitor
US5703088A (en) 1989-08-21 1997-12-30 Beth Israel Deaconess Medical Center, Inc. Topical application of spiperone or derivatives thereof for treatment of pathological conditions associated with immune responses
WO1991003553A1 (en) 1989-09-05 1991-03-21 Immunex Corporation TUMOR NECROSIS FACTOR-α AND -β RECEPTORS
US5395760A (en) 1989-09-05 1995-03-07 Immunex Corporation DNA encoding tumor necrosis factor-α and -β receptors
EP1132471A3 (en) 1989-09-12 2001-11-28 F. Hoffmann-La Roche Ag TNF-binding proteins
JPH03127800A (en) 1989-10-13 1991-05-30 Teijin Ltd Tumor necrosis factor activity inhibitor
DE69022559T2 (en) 1989-12-13 1996-05-02 Yeda Res & Dev Expression of the recombinant tumor necrosis factor binding protein I (TBP-I).
US6673986B1 (en) 1990-01-12 2004-01-06 Abgenix, Inc. Generation of xenogeneic antibodies
ATE356869T1 (en) 1990-01-12 2007-04-15 Amgen Fremont Inc FORMATION OF XENOGENE ANTIBODIES
US5136021A (en) 1990-02-27 1992-08-04 Health Research, Inc. TNF-inhibitory protein and a method of production
US6552170B1 (en) 1990-04-06 2003-04-22 Amgen Inc. PEGylation reagents and compounds formed therewith
US6458360B1 (en) 1990-04-25 2002-10-01 The Johns Hopkins University Soluble complement regulatory molecules
GB2243569A (en) 1990-05-02 1991-11-06 Andrew Langdon Brush with timer
DE59109032D1 (en) 1990-06-28 1998-09-03 Hoechst Ag Fusion proteins with immunoglobulin components, their production and use
WO1992001002A1 (en) 1990-07-11 1992-01-23 Teijin Limited Tumor necrosis factor activity inhibitor and production thereof
DK0567566T4 (en) 1991-01-18 2007-10-22 Amgen Inc Methods for the treatment of tumor necrosis factor-mediated diseases
ATE240740T1 (en) 1991-03-15 2003-06-15 Amgen Inc PEGYLATION OF POLYPEPTIDES
IL99120A0 (en) 1991-08-07 1992-07-15 Yeda Res & Dev Multimers of the soluble forms of tnf receptors,their preparation and pharmaceutical compositions containing them
US5770401A (en) 1991-10-15 1998-06-23 Mullarkey; Michael F. Methods and compositions for treating allergic reactions
US5716805A (en) 1991-10-25 1998-02-10 Immunex Corporation Methods of preparing soluble, oligomeric proteins
ATE207080T1 (en) 1991-11-25 2001-11-15 Enzon Inc MULTIVALENT ANTIGEN-BINDING PROTEINS
CA2133326C (en) 1992-03-30 2005-03-01 Craig A. Smith Fusion proteins comprising tumor necrosis factor receptor
PT639079E (en) 1992-04-30 2000-04-28 Amgen Inc COMPOSITION FOR TREATMENT OF DISEASES MEDIATED BY INTERLEUQUIN-1 AND TUMOR NECROSIS FACTOR
JPH05312248A (en) 1992-05-08 1993-11-22 Nissan Motor Co Ltd Shift level device
JPH07504203A (en) 1992-09-15 1995-05-11 イミュネックス・コーポレーション Method of treating TNF-dependent inflammation using tumor necrosis factor antagonists
JP3720353B2 (en) 1992-12-04 2005-11-24 メディカル リサーチ カウンシル Multivalent and multispecific binding proteins, their production and use
US6562333B1 (en) 1993-06-14 2003-05-13 Schering Corporation Purified mammalian CTLA-8 antigens and related reagents
US6680057B1 (en) 1995-03-23 2004-01-20 Immunex Corporation Methods of treating autoimmune disease by administering interleukin-17 receptor
DK0817847T4 (en) 1995-03-23 2009-10-05 Immunex Corp IL-17 receptor
EP1591529A3 (en) 1995-07-19 2005-11-09 Genetics Institute, LLC Human CLTA-8 and uses of CTLA-8-related proteins
US6074849A (en) 1995-07-19 2000-06-13 Genetics Institute, Inc. Polynucleotides encoding human CTLA-8 related proteins
US6267958B1 (en) 1995-07-27 2001-07-31 Genentech, Inc. Protein formulation
TW555765B (en) 1996-07-09 2003-10-01 Amgen Inc Low molecular weight soluble tumor necrosis factor type-I and type-II proteins
US6406867B1 (en) 1996-08-16 2002-06-18 Human Genome Sciences, Inc. Antibody to human endokine alpha and methods of use
EP0959897B1 (en) 1996-11-27 2009-04-22 Immunex Corporation Method of regulating nitric oxide production
WO1998024893A2 (en) 1996-12-03 1998-06-11 Abgenix, Inc. TRANSGENIC MAMMALS HAVING HUMAN IG LOCI INCLUDING PLURAL VH AND Vλ REGIONS AND ANTIBODIES PRODUCED THEREFROM
US6171586B1 (en) 1997-06-13 2001-01-09 Genentech, Inc. Antibody formulation
US6482923B1 (en) 1997-09-17 2002-11-19 Human Genome Sciences, Inc. Interleukin 17-like receptor protein
ES2333385T3 (en) 1997-09-17 2010-02-19 Human Genome Sciences, Inc. PROTEIN OF THE INTERLEUQUINE TYPE-17.
EP2333069A3 (en) 1998-05-15 2011-09-14 Genentech, Inc. Therapeutic uses of IL-17 homologous polypeptides
JP2000247903A (en) * 1999-03-01 2000-09-12 Chugai Pharmaceut Co Ltd Long-term stabilized pharmaceutical preparation
US6833268B1 (en) 1999-06-10 2004-12-21 Abgenix, Inc. Transgenic animals for producing specific isotypes of human antibodies via non-cognate switch regions
CA2386228A1 (en) 1999-10-04 2001-04-12 Chiron Corporation Stabilized liquid pharmaceutical compositions comprising tissue factor pathway inhibitor (tfpi) polypeptides
AU2001247545A1 (en) 2000-03-16 2001-09-24 Amgen Inc. Il-17 receptor like molecules and uses thereof
AR030554A1 (en) 2000-03-16 2003-08-27 Amgen Inc SIMILAR MOLECULES TO IL-17 RECEPTORS AND USES OF THE SAME
US20030180255A1 (en) 2000-08-24 2003-09-25 Genentech, Inc. IL-17 homologous polypeptides and therapeutic uses thereof
JP2004517918A (en) 2000-10-18 2004-06-17 イミュネックス・コーポレーション Treatment of rheumatoid arthritis using an IL-17 antagonist
JP4583762B2 (en) 2002-02-27 2010-11-17 イミュネックス・コーポレーション Polypeptide preparation
US20050153880A1 (en) 2002-06-27 2005-07-14 Yukio Goto Methods of treating or preventing ibd with il-18
DK1517921T3 (en) 2002-06-28 2006-10-09 Domantis Ltd Immunoglobulin single variable antigen binding domains and double specific constructs thereof
DE10333317A1 (en) 2003-07-22 2005-02-17 Biotecon Therapeutics Gmbh Formulation for protein medicines without the addition of human serum albumin (HSA)
JP2007501251A (en) 2003-08-05 2007-01-25 スリーエム イノベイティブ プロパティズ カンパニー Infection prevention using immune response modifier compounds
GB0321703D0 (en) * 2003-09-16 2003-10-15 Imerys Minerals Ltd Surface modified fillers for polymer resin compositions
EP1712240B1 (en) 2003-12-25 2015-09-09 Kyowa Hakko Kirin Co., Ltd. Stable water-based medicinal preparation containing antibody
IL159670A0 (en) 2003-12-31 2004-06-01 Yeda Res & Dev Use of il-18 binding protein in inflammations
US7285613B2 (en) 2004-06-04 2007-10-23 Designer Molecules, Inc. Free-radical curable polyesters and methods for use thereof
GB0425569D0 (en) 2004-11-19 2004-12-22 Celltech R&D Ltd Biological products
CA2596986A1 (en) 2005-02-14 2006-08-24 Wyeth Use of il-17f in diagnosis and therapy of airway inflammation
WO2006138181A2 (en) 2005-06-14 2006-12-28 Amgen Inc. Self-buffering protein formulations
EP1917030A4 (en) 2005-08-03 2011-03-09 Immunogen Inc Immunoconjugate formulations
CA2915270C (en) 2005-08-05 2017-07-11 Amgen Inc. Stable aqueous protein or antibody pharmaceutical formulations and their preparation
CA2621086A1 (en) 2005-09-01 2007-03-08 Schering Corporation Use of il-23 and il-17 antagonists to treat autoimmune ocular inflammatory disease
EP1931708A1 (en) 2005-10-18 2008-06-18 Zymogenetics, Inc. Il-17c antagonists and methods of using the same
HUE033949T2 (en) 2005-11-01 2018-01-29 Wyeth Llc Sodium chloride solution for drug reconstitution or dilution
EP1977763A4 (en) * 2005-12-28 2010-06-02 Chugai Pharmaceutical Co Ltd Antibody-containing stabilizing preparation
EP1988922A4 (en) * 2006-02-03 2010-06-02 Medimmune Llc Protein formulations
UA99716C2 (en) * 2006-10-02 2012-09-25 Кирин-Амген Инк. Antibody that specifically binds to human il-17 receptor a (il-17ra)
US7767206B2 (en) 2006-10-02 2010-08-03 Amgen Inc. Neutralizing determinants of IL-17 Receptor A and antibodies that bind thereto
WO2008049070A2 (en) 2006-10-18 2008-04-24 Zymogenetics, Inc. Il-17c antagonists and methods of using the same
FR2910324B1 (en) 2006-12-21 2009-03-06 Biomerieux Sa NEW MEDICINE FOR THE TREATMENT OF GASTRIC CANCER
CA2672902C (en) * 2006-12-21 2012-11-27 Amgen Inc. Formulations
GB0700523D0 (en) 2007-01-11 2007-02-21 Insense Ltd The Stabilisation Of Proteins
KR20100015750A (en) 2007-03-26 2010-02-12 지모제넥틱스, 인코포레이티드 Soluble il-17ra/rc fusion proteins and related methods
US20110008356A1 (en) 2007-06-13 2011-01-13 Amgen, Inc. Il-17 heteromeric receptor complex
WO2009006301A2 (en) 2007-06-29 2009-01-08 Battelle Memorial Institute Protein stabilization
MX2010001723A (en) 2007-08-17 2010-04-30 Amgen Inc Formulations of antibodies and fc-fusion molecules using polycations.
MY184345A (en) 2008-02-21 2021-04-01 Amgen Inc Il-17ra-il-17rb antagonists and uses thereof
TW201117824A (en) 2009-10-12 2011-06-01 Amgen Inc Use of IL-17 receptor a antigen binding proteins
PE20121691A1 (en) 2010-01-15 2012-12-14 Kirin Amgen Inc FORMULATION OF ANTIBODIES AND THERAPEUTIC REGIMES
CN107029234A (en) 2010-10-08 2017-08-11 诺华有限公司 Utilize the psoriasic method of the antagonist for treating of IL 17
EP2633317A1 (en) 2010-10-25 2013-09-04 Genentech, Inc. Treatment of gastrointestinal inflammation and psoriasis a
EA201391488A1 (en) * 2011-04-07 2014-01-30 ГЛЭКСОСМИТКЛАЙН ЭлЭлСи COMPOSITIONS WITH REDUCED VISCOSITY
JP2014510152A (en) * 2011-04-07 2014-04-24 グラクソスミスクライン・リミテッド・ライアビリティ・カンパニー Formulation with reduced viscosity
WO2013016220A1 (en) 2011-07-22 2013-01-31 Amgen Inc. Il-17 receptor a is required for il-17c biology
EP3126392B1 (en) 2014-03-31 2019-09-11 Kirin-Amgen, Inc. Methods of treating nail and scalp psoriasis
MY186840A (en) 2014-08-26 2021-08-25 Amgen K A Inc Method for treating psoriasis patient which received anti-tnf-alpha antibody therapy

Also Published As

Publication number Publication date
CY1119852T1 (en) 2018-06-27
JP2013517277A (en) 2013-05-16
ES2753216T3 (en) 2020-04-07
PT3295957T (en) 2019-11-12
NZ601125A (en) 2014-08-29
EA031209B9 (en) 2021-11-19
KR20120118036A (en) 2012-10-25
EA031209B1 (en) 2018-12-28
AU2011205402B2 (en) 2015-02-05
WO2011088120A9 (en) 2012-08-09
MX349856B (en) 2017-08-16
LT2523688T (en) 2018-03-12
MA33989B1 (en) 2013-02-01
US11505612B2 (en) 2022-11-22
CN102821787B (en) 2015-07-29
UA112288C2 (en) 2016-08-25
EA201891433A2 (en) 2018-11-30
RS59743B1 (en) 2020-02-28
CL2012001966A1 (en) 2013-01-18
DK2523688T3 (en) 2017-12-04
SG10201604093XA (en) 2016-07-28
US10808033B2 (en) 2020-10-20
US20150017184A1 (en) 2015-01-15
MX2012008213A (en) 2012-11-06
SI3295957T1 (en) 2020-02-28
HUE046670T2 (en) 2020-03-30
PL3295957T3 (en) 2020-03-31
US20230192873A1 (en) 2023-06-22
EP3632466A1 (en) 2020-04-08
CR20120419A (en) 2012-11-29
AU2011205402A1 (en) 2012-07-12
EP3295957B1 (en) 2019-08-07
JP5743234B2 (en) 2015-07-01
AU2017216579A1 (en) 2017-09-07
SI2523688T1 (en) 2018-03-30
US20130022621A1 (en) 2013-01-24
WO2011088120A8 (en) 2012-09-13
ES2652637T3 (en) 2018-02-05
US10072085B2 (en) 2018-09-11
US20180346583A1 (en) 2018-12-06
WO2011088120A1 (en) 2011-07-21
EA201290653A1 (en) 2013-02-28
HUE035618T2 (en) 2018-05-28
CY1122466T1 (en) 2020-10-14
TN2012000335A1 (en) 2013-12-12
EP3295957A1 (en) 2018-03-21
LT3295957T (en) 2020-01-27
DK3295957T3 (en) 2019-10-14
TW201129382A (en) 2011-09-01
BR112012017150B1 (en) 2022-03-03
PL2523688T3 (en) 2018-04-30
EP2523688A1 (en) 2012-11-21
CN102821787A (en) 2012-12-12
AR079903A1 (en) 2012-02-29
US8883151B2 (en) 2014-11-11
RS56781B1 (en) 2018-04-30
MY182680A (en) 2021-01-29
CO6640206A2 (en) 2013-03-22
AU2015202023A1 (en) 2015-05-14
IL220602B (en) 2019-03-31
AU2015202023B2 (en) 2017-05-18
PT2523688T (en) 2018-01-05
EP2523688B1 (en) 2017-10-11
CA2787128A1 (en) 2011-07-21
KR101766936B1 (en) 2017-08-09
JP2015052017A (en) 2015-03-19
HRP20171939T1 (en) 2018-03-23
EA201891433A3 (en) 2019-02-28
SG182468A1 (en) 2012-08-30
BR112012017150A2 (en) 2017-10-10
US20200399384A1 (en) 2020-12-24
PE20121691A1 (en) 2012-12-14
TWI554282B (en) 2016-10-21
ZA201205167B (en) 2013-03-27
CA2787128C (en) 2019-06-11
NO2523688T3 (en) 2018-03-10

Similar Documents

Publication Publication Date Title
IN2012DN06720A (en)
PH12015500940A1 (en) Bruton`s tyrosine kinase inhibitors
SG10201808102WA (en) Bicyclic heterocycle compounds and their uses in therapy
MX344238B (en) Tetrazole compounds and methods of making and using same.
MX2014009757A (en) Isoindoline derivatives, pharmaceutical compositions containing them, and their use in therapy.
IN2014DN09434A (en)
IN2015DN00376A (en)
EP2528603A4 (en) Pharmaceutical compositions for the treatment of pain and other indicatons
MX2012007806A (en) Pharmaceutical compositions for oral administration of insulin peptides.
IL224544B (en) Compound useful for the treatment of nonsense-mutation-mediated diseases and pharmaceutical composition comprising said compound
MX2013009764A (en) Cannabinoid receptor modulators.
MX347734B (en) S100a4 antibodies and therapeutic uses thereof.
ZA201108305B (en) Novel p2x7r antagonists and their use
EA201201658A1 (en) DERIVATIVES OF PIPERIDINE AND THEIR APPLICATION FOR THE TREATMENT OF METABOLIC DISORDERS
IN2015DN03921A (en)
GB2523707A (en) Novel pharmaceutical formulations and their use in the treatment of periodontal disease
MX2014001393A (en) Substituted 3-(biphenyl-3-yl)-4-hydroxy-8-methoxy-1-azaspiro[4.5] dec-3-en-2-one.
UY33219A (en) CYCLIC CETOENOLS FOR THERAPIES
MX2013002118A (en) Substituted 2-oxy-quinoline-3-carboxamides as kcnq2/3 modulators.
DE102009018133A8 (en) Pharmaceutical composition for the treatment of dermatological autoimmune diseases
GB201317815D0 (en) Oral supplementation for the reversal of human hair canities
UA112981C2 (en) OPTION OF HUMAN GDNF
MX2013002295A (en) Substituted 1-oxo-dihydroisoquinoline-3-carboxamides as kcnq2/3 modulators.
EA201500446A1 (en) PHARMACEUTICAL COMPOSITION TO REDUCE N-OXIDE TRIMETYLAMINE LEVEL
TN2013000336A1 (en) 5s,8s)-3-(4'-chlor-3'-fluoro-4-methylbiphenyl-3-yl)-4-hydroxy-8-methoxy-1-azaspiro[4.5]dec-3-en-2-one (compound a) for therapy.